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of Atrial Septal Defects*
Emile Bacha, MDT he study by Ooi et al. (1) in this issue of JACC:Cardiovascular Interventions attempts tocompare the “value” (deﬁned as outcomes
relative to cost) of transcatheter versus surgical
closure of atrial septal defects (ASD). They used
the Pediatric Health Information System (PHIS) data-
base, one of the largest national pediatric databases.
They appropriately excluded patients younger than
1 year of age or patients with other confounding
factors, attempting to focus on “typical” patients in
need for elective ASD closure. They found that
patients undergoing transcatheter ASD closure were
signiﬁcantly older, had a shorter length of stay
(LOS), and were less likely to have an infection or a
post-procedural complication. As expected given the
shorter LOS, the cost for the transcatheter group
was signiﬁcantly less. There was no mortality in
either group.SEE PAGE 79Of course, PHIS is a retrospective administrative
database abstracted from medical records, so the
terms “complications” and “infection” can have a
vastly different meaning than for a practicing
physician. I would have preferred to have a clear
deﬁnition and description of these two terms so
that we understand what they mean in this context.
The contribution of complications to LOS for both
groups was only 0.7 days and to cost for the sur-
gical group only $1,500, suggesting that the surgical
complications were not serious. Nevertheless, both
groups were analyzed the same way, the numbers*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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analyzed), and thus the differences among groups
are real and probably reﬂect the situation in the real
world.
Although I strongly support this effort, which
helps us further deﬁne the indications for surgical
versus transcatheter ASD closure, the authors may
be asking the wrong question. I would argue that
value in the clinical sense supersedes the notion of
value taught in business schools. Should we really
send all ASDs for device closure to save an average
of $6,231 per patient? Of course not, and that is also
not what the authors are concluding or endorsing.
With excellent short-term surgical safety further
validated in this study (0% mortality for 3,159 open-
heart ASD repairs), outstanding very long-term sur-
gical ASD data published and available (2,3), and at
least one large long-term comparative study showing
a higher reintervention rate for transcatheter ASD
closure (4), what we really need to know is the long-
term clinical value for a given patient. The device
erosion rate is still at an estimated 0.1% to 0.3%,
with no known equivalent long-term risk for surgical
patients (5,6).
Finally, it is well known that hospital costs and
charges are completely arbitrary and variable from
hospital to hospital. This is further evidenced by
the complete randomness of median transcatheter
and surgical cost of ASD closures seen in Figures 3
and 4 of the Ooi et al. (1) study. It is therefore difﬁcult
to individualize these results for a single patient in
any given hospital. A few hospitals had even lower
surgical costs compared with transcatheter! The
transcatheter and surgical ASD closure distribution
ﬁgure (Fig. 2) is also interesting in that it suggests
that the indications for transcatheter versus
surgical ASD closures have not matured yet. Some
hospitals favor surgery while others (the majority)
use the transcatheter approach predominantly. I
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88suspect this ratio is dependent on more than clin-
ical factors, such as availability of interventional
cardiologists skilled at ASD closures, cultural fac-
tors, and others.
In conclusion, this is an important study that
helps us further deﬁne the role of surgical versus
transcatheter approaches for ASD closure. However,
as the authors have noted themselves, one has to
keep in mind that the value comparison studied hereis really a snapshot value of what happens during the
index hospitalization, not a reﬂection of value gained
over a lifetime.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Emile Bacha, Department of Surgery, Columbia
University/NewYork-Presbyterian, 3959 Broadway,
New York, New York 10032. E-mail: eb2709@
columbia.edu.RE F E RENCE S1. Ooi YK, Kelleman M, Ehrlich A, et al. Trans-
catheter versus surgical closure of atrial septal
defects in children: a value comparison. J Am Coll
Cardiol Intv 2016;9:79–86.
2. Roos-Hesselink JW,MeijboomFJ, SpitaelsSE, etal.
Excellent survival and low incidence of arrhythmias,
stroke and heart failure long-term after surgical
ASD closure at young age: a prospective follow-up
study of 21–33 years. Eur Heart J 2003;24:190–7.
3. Murphy JG, Gersh BJ, McGoon MD, et al. Long-
term outcome after surgical repair of isolatedatrial septal defect: follow-up at 27 to 32 years.
N Engl J Med 1990;323:1645–50.
4. Kotowycz MA, Therrien J, Ionescu-Ittu R,
et al. Long-term outcomes after surgical
versus transcatheter closure of atrial septal de-
fects in adults. J Am Coll Cardiol Intv 2013;6:
497–503.
5. Moore J, Hegde S, El-Said H, et al. Trans-
catheter device closure of atrial septal defects.
A safety review. J Am Coll Cardiol 2013;6:
433–42.6. DiBardino DJ, McElhinney DB, Kaza AK,
Mayer JE Jr. Analysis of the US Food and Drug
Administration Manufacturer and User Facility
Device Experience database for adverse events
involving Amplatzer septal occluder devices and
comparison with the Society of Thoracic Surgery
congenital cardiac surgery database. J Thorac
Cardiovasc Surg 2009;137:1334–41.
KEY WORDS atrial septal defect,
interventional cardiology, surgery
